The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Emerging treatment strategies for extramedullary myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment approaches for extramedullary disease (EMD) in relapsed/refractory (R/R) multiple myeloma. He highlights the challenges associated with EMD, particularly following immunotherapy, and explores emerging treatment strategies including melflufen and selinexor, while emphasizing the need for further research into combination approaches and therapies targeting the biology of EMD. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
